EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal amyloid PET changes by cerebrospinal fluid amyloid and tau profiles in individuals with normal cognition: Role of APOE ε4

Marianna Rizzo iD, Julie E Oomens iD, Willemijn J Jansen iD, Pieter Jelle Visser iD, Stephanie J B Vos iD, AMYPAD consortium

Journal of Alzheimer’s Disease · 2026-07 · 112 (2) · 875-885

DOI: 10.1177/13872877261453099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 30.05.2026. Verfasst von Marianna Rizzo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, Mental Health and Neuroscience Research Institute, Maastricht University, Ma…. Hauptthemen laut MEDLINE: tau Proteins, Apolipoprotein E4, Amyloid beta-Peptides, Cognition. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identifying factors associated with early progression of cortical amyloid deposition is crucial for understanding Alzheimer's disease (AD) pathophysiology, yet these remain unclear.

Objective

To investigate the associations of AD cerebrospinal fluid (CSF) biomarkers with early longitudinal amyloid deposition on positron emission tomography (PET), and the impact of APOE ε4 carriership.

Methods

We selected cognitively unimpaired participants with baseline data on CSF amyloid and p-tau181, APOE ε4 carriership, and ≥ 2 consecutive amyloid PET assessments from the AMYPAD-PNHS cohort. Linear mixed models were used to investigate the associations of combinations of amyloid abnormality (A+) and tau abnormality (T+) in CSF (A+T+, A+T-, A-T+, A-T-), without and with stratification for APOE ε4 carriership, with longitudinal global cortical amyloid deposition on PET, measured in Centiloids.

Results

We included 329 individuals (mean age 63.5 [SD 6.1], 58% female, 49% APOE ε4 carriers). Longitudinally, CSF profiles with abnormal amyloid levels (A+T+, A+T-) showed greater increases in cortical amyloid deposition than profiles with normal amyloid levels (A-T+, A-T-), irrespective of CSF tau abnormality (all p < 0.001). Only for CSF profiles with normal amyloid levels, longitudinal amyloid deposition depended on APOE ε4 carriership, with both A-T+ and A-T- showing increased deposition among APOE ε4 carriers (carriers versus non-carriers: A-T+ p = 0.006, A-T- p = 0.016).

Conclusions

In cognitively unimpaired individuals, longitudinal increase in cortical amyloid deposition was mainly associated with abnormal baseline CSF amyloid rather than tau. APOE ε4 carriership was associated with increased longitudinal cortical amyloid deposition only in individuals with normal baseline CSF amyloid. These findings inform early AD pathological progression and trial design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsApolipoprotein E4Amyloid beta-PeptidesCognitionAmyloidHumansFemalePositron-Emission TomographyLongitudinal StudiesMaleAgedMiddle AgedBiomarkers

Stichwörter der Autor:innen

Alzheimer's diseaseApolipoprotein E4amyloidamyloid-β peptidescerebrospinal fluidcohort studieslongitudinal studiespositron emission tomographytau proteins

Substanzen

tau ProteinsApolipoprotein E4Amyloid beta-PeptidesBiomarkersAmyloid

Autor:innen und Institutionen

  • Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, Netherlands.
  • Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands.
  • Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
  • Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Marianna Rizzo, Julie E Oomens, Willemijn J Jansen, Pieter Jelle Visser, Stephanie J B Vos

Förderung

  • Innovative Medicines Initiative

Zitieren

APA

Rizzo, M., Oomens, J. E., Jansen, W. J., Visser, P. J., Vos, S. J. B., & AMYPAD consortium (2026). Longitudinal amyloid PET changes by cerebrospinal fluid amyloid and tau profiles in individuals with normal cognition: Role of APOE ε4. Journal of Alzheimer’s Disease, 112(2), 875-885. https://doi.org/10.1177/13872877261453099

Vancouver

Rizzo M, Oomens JE, Jansen WJ, Visser PJ, Vos SJB, AMYPAD consortium. Longitudinal amyloid PET changes by cerebrospinal fluid amyloid and tau profiles in individuals with normal cognition: Role of APOE ε4. Journal of Alzheimer’s Disease. 2026;112(2):875-885. doi:10.1177/13872877261453099

BibTeX
@article{Rizzo2026,
  author = {Rizzo, Marianna and Oomens, Julie E and Jansen, Willemijn J and Visser, Pieter Jelle and Vos, Stephanie J B and AMYPAD consortium, AMYPAD consortium},
  title = {Longitudinal amyloid PET changes by cerebrospinal fluid amyloid and tau profiles in individuals with normal cognition: Role of APOE ε4},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  volume = {112},
  number = {2},
  pages = {875--885},
  doi = {10.1177/13872877261453099}
}
Kostenlos starten →